JMP Securities Maintains Market Outperform on Cidara Therapeutics, Raises Price Target to $173
Author: Benzinga Newsdesk | October 03, 2025 07:07am
JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:CDTX) with a Market Outperform and raises the price target from $153 to $173.